INTRODUCTION
Normal tissue vasculature cannot support tumor growth beyond 2 mm in diameter [1] . Formation of new vessels is needed for tumor development as well as invasion and metastasis [1] . Tumor neovascularization is an interesting target for chemotherapy because, in general, adult endothelial cells are quiescent except for the menstrual cycle [2] . Furthermore, this process is regulated by cell-surface receptors and extracellular factors, which means that drugs can interfere with neovascularization without
Vasculogenesis
Vasculogenesis is the mechanism of blood vessel formation in the embryo: hematopoietic precursor cells line blood vessels and develop into blood islands [5] . Centrally located cells develop into blood cells, whereas peripheral cells develop into endothelial cells [5] . Recent studies have shown a similar process in tumors in experimental animal models, in which precursor cells from the bone marrow circulate, aggregate, and mesh into new blood vessels [6] . The importance of postnatal vasculogenesis to human tumors is unknown and therefore its relevance as a target for cancer therapy remains undecided.
Angiogenesis
This process is probably the essential mechanism for tumor neovascularization, and drugs inhibiting angiogenesis are currently being evaluated in clinical trials. Angiogenesis consists of several steps [7] . Endothelial cells that form the wall of existing small blood vessels are activated, degrade the extracellular matrix, migrate through the matrix, and proliferate. The new endothelial cells organize into hollow tubes, which ultimately anastomose to form new capillaries.
ANGIOGENESIS STIMULI
Angiogenesis is induced when the balance between proangiogenic and antiangiogenic factors is disturbed. In tumors, this imbalance may be caused by either hypoxia (low oxygen tension) or genetic alterations that activate oncogenes and/or inactivate tumor suppressor genes [8] (Fig. 1) .
Hypoxia
Using oxygen that diffuses from existing vessels, a tumor grows until oxygen demand exceeds supply. The ensuing hypoxia induces tumor cells to generate, via both increased transcription (regulated by the hypoxia-induced transcription factor HIF1a) and increased mRNA stabilization, a series of proangiogenic factors that function as highly specific growth factors/survival factors for endothelial cells [9] . Among these factors are VEGF, FGF, transforming growth factor β, and tumor necrosis factor α. VEGF and FGF are considered the most important mediators in tumor angiogenesis. VEGF (VEGF-A) induces proliferation of vascular endothelial cells [10] [11] [12] [13] , promotes [8] . survival of endothelial cells in newly formed vessels [14] [15] [16] [17] , and increases blood vessel permeability [18, 19] . Through increased blood vessel permeability, VEGF allows creation of an extravascular fibrin gel that supports endothelial cell growth [20, 21] . This permits increased tumor growth resulting in hypoxia, which in turn leads to VEGF production (Fig. 1 ).
Oncogenes and Tumor Suppressor Genes
In many tumors, angiogenesis is induced not by hypoxia, but by genetic alterations. The loss of function of tumor suppressor genes such as VHL, p53, and p16
INK4a , or the activation of oncogenes including ras, raf, HER2/erbB2 (neu), and src, results in increased expression and/or secretion of VEGF [22] [23] [24] [25] [26] [27] (Fig. 1) , Madrid, Spain) and will be described in more detail in the next section.
ras Induction of Angiogenesis in Skin Tumors
The mouse skin carcinogenesis model, in which mice are treated with the genotoxic 7,12-dimethylbenz-[a]anthracene followed by multiple topical applications of 12-O-tetradecanoylphorbol-13-acetate as a promoter, allows observation of the sequential stages of tumor development [28, 29] . Hyperplastic skin gives rise to papillomas, which are benign exophytic lesions. These lesions eventually transform into squamous cell carcinoma (SCC), which is practically identical to human head and neck SCC and human skin SCC. The initiating mutation in this model is an A→T transversion in codon 61 of the H-ras gene [30, 31] . Larcher et al. showed an upregulation of VEGF mRNA and protein in papillomas and a further increase in SCC [22] . They confirmed mutant H-ras involvement in the VEGF upregulation by showing that transduction of keratinocytes with this activated oncogene in normal oxygen conditions markedly induced VEGF mRNA levels [22] . This finding is consistent with other reports demonstrating ras-dependence of VEGF induction in human colon carcinoma cells, H-ras transformed rat intestinal epithelial cells, and NIH 3T3 cells stably transfected with v-H-ras or v-raf [32, 33] . Furthermore, increased expression of the epidermal growth factor receptor (EGFR) in SCC has been found in association with H-ras activation [34] [35] [36] .
In collaboration with our laboratory, Dr. Jorcano and colleagues studied the role of EGFR in mutant H-rasinduced angiogenesis. An ex vivo experiment with tumor cells carrying mutant H-ras and transfected with dominantnegative (DN) EGFR showed that DN EGFR cells formed smaller tumors in nude mice compared with control cells [37] . In transgenic mice that harbor DN EGFR under control of the keratin 5 promoter, chemical induction of skin tumors resulted in small papillomas containing narrow blood vessels, whereas the papillomas from control animals displayed large vessels [37] . These experiments demonstrate that a functional EGFR is required for mutant H-ras induction of angiogenesis in skin tumors; because mutant H-ras is a downstream effector of EGFR, this may appear paradoxical. However, a recent report suggested cell typespecific modes of VEGF regulation by the mutant ras oncogene [38] .
Analysis of vasculature in the sequential skin tumor stages by immunohistochemical staining of the endothelial cell marker CD31 [39] has shown that blood vessel density increases considerably in very early papillomas [40] . In more advanced papillomas as well as SCC, blood vessel density stabilizes but the size of the blood vessels increases [40] . Large blood vessels also have been observed following hyperproliferative stimuli in the dermis of transgenic mice that express mouse VEGF 120 (1 of 3 VEGF isoforms that is not bound to extracellular proteins, but is freely diffusible) under control of the keratin 6 promoter [41] . Endothelial cell proliferation is detectable in the vessels present in papillomas and SCC, indicating that these cells are proliferating. Although various markers have been reported that are expressed differentially in proliferating versus quiescent endothelial cells in vivo [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] , no markers expressed exclusively in tumor endothelium have been detected. In hyperplastic skin, VEGF production by keratinocytes has been demonstrated by immunohistochemistry; VEGF production increases in papillomas and stabilizes in more advanced stages (Franco and Conti, unpublished results). We believe that the increase in VEGF in SCC, which was previously detected by Western blot analysis [41] , reflects the tumor cell mass rather than the amount produced by individual cells. Interestingly, immunohistochemical detection of VEGF in SCC shows no association with anoxic areas, confirming that angiogenesis in these tumors is not induced by hypoxia/anoxia. Demonstrating proof of principle by deletion of VEGF function in vivo has not been feasible. VEGF-knockout mice are lethal [54] [55] [56] and only recently a few conditional VEGF-knockout mice, with abrogated VEGF expression in the epidermis, were obtained in our laboratory. Abbreviations: AML = acute myeloid leukemia; FGF = fibroblast growth factor; mAb = monoclonal antibody; rHu = recombinant humanized; PDGF = platelet-derived growth factor; VEGF = vascular endothelial growth factor; VEGFR = vascular endothelial growth factor receptor. Consequently, the use of an anti-VEGF antibody and small molecule tyrosine kinase inhibitors to interfere with VEGF signaling is being investigated in clinical trials in cancer patients. Table 1 shows a list of drugs that are being developed to target VEGF function . These agents, like other antiangiogenic drugs, are cytostatic to the tumor cells. Therefore, several of the anti-VEGF drugs that currently are being tested in ongoing clinical trials as single agents, also are being tested in combination with conventional cytotoxic chemotherapeutics, such as cisplatin, carboplatin, gemcitabine, fluorouracil, paclitaxel, and docetaxel (see also: http://www.cancer.gov/search/ clinical_trials/).
Antiangiogenic Factors
Proteolysis is an important component of angiogenesis. It is involved in degradation of the basement membrane and the extracellular matrix, release of growth factors bound to the matrix (including VEGF and FGF, which are bound to extracellular proteins), and remodeling of the matrix. Finally, Folkman and colleagues showed that tumors themselves secrete antiangiogenic factors that are generated upon proteolysis of large precursor proteins [88] . The endogenous antiangiogenic factors angiostatin and endostatin are proteolytic fragments of plasminogen and collagen VIII, respectively [88, 89] . Angiostatin and endostatin inhibit proliferation and migration of endothelial cells, and induce endothelial cell apoptosis [88, [90] [91] [92] [93] [94] . Although the mechanism of action of endostatin is still unclear, the actions of angiostatin are most likely mediated via a cell surface ATP synthase [90] . Both antiangiogenic factors currently are undergoing testing in phase I clinical trials.
CONCLUSIONS
The relevance of angiogenesis to tumor development is unquestioned and a number of clinical trials are ongoing, testing agents that directly target angiogenesis, such as anti-VEGF drugs and endogenous antiangiogenic factors.
The angiogenesis studies in the mouse skin carcinogenesis model described in this article suggest that inhibition of oncogene signal transduction pathways may indirectly inhibit angiogenesis. Indeed, signal transduction inhibitors are thought to indirectly downregulate VEGF expression in tumor cells and thus block angiogenesis [95] . Angiogenesis also may be targeted indirectly in other therapies. The cyclin-dependent kinase inhibitor flavopiridol has been shown to decrease VEGF production [96] , while conventional chemotherapy has been shown to have antiangiogenic effects [95, 97] .
In the near future, the outcome of ongoing clinical trials will give us more insights into the potential of antiangiogenic approaches to treat cancer.
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